Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06924658
PHASE2

Metformin in Safety and Efficacy in Gouty Patients

Sponsor: Mostafa Bahaa

View on ClinicalTrials.gov

Summary

The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients

Official title: the Impact of Metformin Use on Clinical Outcomes in Gouty Patients

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2025-04-20

Completion Date

2026-11-20

Last Updated

2025-06-27

Healthy Volunteers

No

Conditions

Interventions

OTHER

placebo

Placebo will have the same look of metformin

DRUG

Metformin

Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients

Locations (1)

Tanta Unuversity

Tanta, Egypt